PubMed

Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus.

Hare KJ, Knop FK, Asmar M, Madsbad S, Deacon CF, Holst JJ, Vilsbøll T.

J Clin Endocrinol Metab. 2009 Oct 16. [Epub ahead of print]PMID: 19837930 [PubMed - as supplied by publisher]Related articles

Immunoassays for the incretin hormones GIP and GLP-1.

Deacon CF, Holst JJ.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):425-32.PMID: 19748060 [PubMed - in process]Related articles

Inhibition of neutral endopeptidase 24.11 does not potentiate the improvement in glycemic control obtained with dipeptidyl peptidase-4 inhibition in diabetic Goto-Kakizaki rats.

Simonsen L, Pilgaard S, Carr RD, Kanstrup AB, Holst JJ, Deacon CF.

Horm Metab Res. 2009 Nov;41(11):851-3. Epub 2009 Jul 3. No abstract available. PMID: 19579179 [PubMed - in process]Related articles

Long-term exendin-4 treatment delays natural deterioration of glycaemic control in diabetic Goto-Kakizaki rats.

Simonsen L, Pilgaard S, Orskov C, Hartmann B, Holst JJ, Deacon CF.

Diabetes Obes Metab. 2009 Sep;11(9):884-90. Epub 2009 Jun 5.PMID: 19508463 [PubMed - in process]Related articles

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Deacon CF, Holst JJ.

Adv Ther. 2009 May;26(5):488-99. Epub 2009 May 14.PMID: 19444391 [PubMed - in process]Related articles

Potential of liraglutide in the treatment of patients with type 2 diabetes.

Deacon CF.

Vasc Health Risk Manag. 2009;5(1):199-211. Epub 2009 Apr 8. Review.PMID: 19436648 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men.

Lindgren O, Mari A, Deacon CF, Carr RD, Winzell MS, Vikman J, Ahrén B.

J Clin Endocrinol Metab. 2009 Aug;94(8):2887-92. Epub 2009 May 12.PMID: 19435824 [PubMed - indexed for MEDLINE]Related articles

Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.

Vollmer K, Gardiwal H, Menge BA, Goetze O, Deacon CF, Schmidt WE, Holst JJ, Meier JJ.

J Clin Endocrinol Metab. 2009 Apr;94(4):1379-85. Epub 2009 Jan 27.PMID: 19174495 [PubMed - indexed for MEDLINE]Related articles

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T.

J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. Epub 2008 Dec 2.PMID: 19050053 [PubMed - indexed for MEDLINE]Related articles

Overnight hypoxic exposure and glucagon-like peptide-1 and leptin levels in humans.

Snyder EM, Carr RD, Deacon CF, Johnson BD.

Appl Physiol Nutr Metab. 2008 Oct;33(5):929-35.PMID: 18923568 [PubMed - indexed for MEDLINE]Related articlesFree article

The incretin system and its role in type 2 diabetes mellitus.

Holst JJ, Vilsbøll T, Deacon CF.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. Epub 2008 Aug 20. Review.PMID: 18786605 [PubMed - indexed for MEDLINE]Related articles

Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

Carr RD, Larsen MO, Winzell MS, Jelic K, Lindgren O, Deacon CF, Ahrén B.

Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E779-84. Epub 2008 Jul 8.PMID: 18612044 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.

Foley JE, Ligueros-Saylan M, He YL, Holst JJ, Deacon CF, Dunning BE, Leone-Jones A, Yu T, Kelley DE.

Horm Metab Res. 2008 Oct;40(10):727-30. Epub 2008 Jul 2. No abstract available. PMID: 18597213 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Madsbad S, Krarup T, Deacon CF, Holst JJ.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. Review.PMID: 18542012 [PubMed - indexed for MEDLINE]Related articles

Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

Deacon CF.

Curr Opin Investig Drugs. 2008 Apr;9(4):402-13. Review.PMID: 18393107 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide-1, glucose homeostasis and diabetes.

Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S.

Trends Mol Med. 2008 Apr;14(4):161-8. Epub 2008 Mar 18. Review.PMID: 18353723 [PubMed - indexed for MEDLINE]Related articles

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.

Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44. Epub 2008 Mar 10.PMID: 18331607 [PubMed - indexed for MEDLINE]Related articles

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.

Deacon CF, Carr RD, Holst JJ.

Front Biosci. 2008 Jan 1;13:1780-94. Review.PMID: 17981667 [PubMed - indexed for MEDLINE]Related articles

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Deacon CF.

Diabetes Obes Metab. 2007 Sep;9 Suppl 1:23-31. Review.PMID: 17877544 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.

Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE.

Diabetes Care. 2008 Jan;31(1):108-13. Epub 2007 Oct 1.PMID: 17909087 [PubMed - indexed for MEDLINE]Related articlesFree article

Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

He YL, Serra D, Wang Y, Campestrini J, Riviere GJ, Deacon CF, Holst JJ, Schwartz S, Nielsen JC, Ligueros-Saylan M.

Clin Pharmacokinet. 2007;46(7):577-88.PMID: 17596103 [PubMed - indexed for MEDLINE]Related articles

Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.

He YL, Wang Y, Bullock JM, Deacon CF, Holst JJ, Dunning BE, Ligueros-Saylan M, Foley JE.

J Clin Pharmacol. 2007 May;47(5):633-41.PMID: 17442688 [PubMed - indexed for MEDLINE]Related articles

Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats.

Simonsen L, Pilgaard S, Orskov C, Rosenkilde MM, Hartmann B, Holst JJ, Deacon CF.

Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G288-95. Epub 2007 Apr 12.PMID: 17431213 [PubMed - indexed for MEDLINE]Related articlesFree article

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

Deacon CF.

Expert Opin Investig Drugs. 2007 Apr;16(4):533-45. Review.PMID: 17371200 [PubMed - indexed for MEDLINE]Related articles

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.

Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA.

Diabetologia. 2007 Apr;50(4):806-13. Epub 2007 Feb 16.PMID: 17334652 [PubMed - indexed for MEDLINE]Related articles

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV.

Hansen L, Hare KJ, Hartmann B, Deacon CF, Ugleholdt RK, Plamboeck A, Holst JJ.

Regul Pept. 2007 Feb 1;138(2-3):126-32. Epub 2006 Nov 14.PMID: 17107718 [PubMed - indexed for MEDLINE]Related articles

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

Vilsbøll T, Agersø H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, Krarup T, Holst JJ.

Regul Pept. 2006 Dec 10;137(3):168-72. Epub 2006 Aug 28.PMID: 16934887 [PubMed - indexed for MEDLINE]Related articles

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsbøll T.

Eur J Endocrinol. 2006 Sep;155(3):485-93.PMID: 16914604 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.PMID: 16912128 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice.

Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahrén B.

Endocrinology. 2006 Jul;147(7):3173-80. Epub 2006 Apr 20.PMID: 16627575 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.

Meier JJ, Nauck MA, Kask B, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B.

World J Gastroenterol. 2006 Mar 28;12(12):1874-80.PMID: 16609993 [PubMed - indexed for MEDLINE]Related articlesFree article

GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

Deacon CF, Plamboeck A, Rosenkilde MM, de Heer J, Holst JJ.

Am J Physiol Endocrinol Metab. 2006 Sep;291(3):E468-75. Epub 2006 Apr 11.PMID: 16608883 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucose-stimulated prehepatic insulin secretion is associated with circulating alanine, triglyceride, glucagon, lactate and TNF-alpha in patients with HIV-lipodystrophy.

Haugaard SB, Andersen O, Pedersen SB, Dela F, Deacon CF, Holst JJ, Iversen J, Madsbad S.

HIV Med. 2006 Apr;7(3):163-72.PMID: 16494630 [PubMed - indexed for MEDLINE]Related articles

Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.

Simonsen L, Holst JJ, Deacon CF.

Diabetologia. 2006 Apr;49(4):706-12. Epub 2006 Jan 31.PMID: 16447056 [PubMed - indexed for MEDLINE]Related articles

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.

Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. Epub 2006 Jan 10.PMID: 16403774 [PubMed - indexed for MEDLINE]Related articlesFree article

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.

Zander M, Madsbad S, Deacon CF, Holst JJ.

Diabetologia. 2006 Feb;49(2):369-74. Epub 2005 Dec 30.PMID: 16385384 [PubMed - indexed for MEDLINE]Related articles

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

Deacon CF, Holst JJ.

Int J Biochem Cell Biol. 2006;38(5-6):831-44. Epub 2005 Oct 3. Review.PMID: 16242377 [PubMed - indexed for MEDLINE]Related articles

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

Plamboeck A, Holst JJ, Carr RD, Deacon CF.

Diabetologia. 2005 Sep;48(9):1882-90. Epub 2005 Jul 16.PMID: 16025254 [PubMed - indexed for MEDLINE]Related articles

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA.

Diabetologia. 2005 Sep;48(9):1872-81. Epub 2005 Jul 12.PMID: 16010522 [PubMed - indexed for MEDLINE]Related articles

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.

Schou JH, Pilgaard K, Vilsbøll T, Jensen CB, Deacon CF, Holst JJ, Vølund A, Madsbad S, Vaag AA.

J Clin Endocrinol Metab. 2005 Aug;90(8):4912-9. Epub 2005 May 17.PMID: 15899957 [PubMed - indexed for MEDLINE]Related articlesFree article

MK-431 (Merck).

Deacon CF.

Curr Opin Investig Drugs. 2005 Apr;6(4):419-26. Review.PMID: 15898349 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.

Andersen O, Haugaard SB, Holst JJ, Deacon CF, Iversen J, Andersen UB, Nielsen JO, Madsbad S.

HIV Med. 2005 Mar;6(2):91-8.PMID: 15807714 [PubMed - indexed for MEDLINE]Related articles

What do we know about the secretion and degradation of incretin hormones?

Deacon CF.

Regul Pept. 2005 Jun 15;128(2):117-24. Review.PMID: 15780431 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Holst JJ, Deacon CF.

Diabetologia. 2005 Apr;48(4):612-5. Epub 2005 Mar 10. No abstract available. PMID: 15759106 [PubMed - indexed for MEDLINE]Related articles

Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.

Gram DX, Hansen AJ, Deacon CF, Brand CL, Ribel U, Wilken M, Carr RD, Svendsen O, Ahrén B.

Eur J Pharmacol. 2005 Feb 21;509(2-3):211-7.PMID: 15733558 [PubMed - indexed for MEDLINE]Related articles

Circulation and degradation of GIP and GLP-1.

Deacon CF.

Horm Metab Res. 2004 Nov-Dec;36(11-12):761-5. Review.PMID: 15655705 [PubMed - indexed for MEDLINE]Related articles